Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers
Authors:
- P. GeorgiouPGP. Georgiou
- K. HowlandKHK. Howland
- M. DennisMDM. Dennis
- C. H. ComptonCCC. H. Compton
- N. C. BarnesNBN. C. Barnes
Open Access
Abstract
BACKGROUND: There is increasing evidence to show that leukotrienes are important mediators in asthma. Leukotriene receptor antagonists protect against antigen and exercise challenges in patients with chronic asthma. A study was undertaken to investigate the activity of the leukotriene receptor antagonist pranlukast (SB 205312, ONO-1078) in blocking bronchoconstriction induced by leukotriene D4 (LTD4) inhalation. The selectivity of pranlukast was evaluated using histamine challenge. METHODS: Pranlukast, 450 mg twice daily, was given to eight healthy non-smoking men for five days in a randomised, double blind, placebo controlled, crossover study. The specific airways conductance (sGaw) was measured before and after bronchial provocation with inhaled LTD4 at 3.5 hours after the first dose and at 3.5 and 9.5 hours after the last dose of pranlukast on the morning of day 5. The concentration of LTD4 required to produce a fall in sGaw of 35% (PC35) was calculated. Subjects also underwent a histamine challenge 3.5 hours after a single dose of pranlukast, 450 mg, or placebo. RESULTS: A single dose of pranlukast produced a 10.6 fold increase in PC35sGaw (95% confidence interval (CI) 4.4 to 25.5; p < 0.001) for LTD4 at 3.5 hours after dosing compared with placebo. Three and a half hours after the morning dose of pranlukast on day 5 the PC35sGaw for LTD4 was increased 25.9 fold (95% CI 10.8 to 62.2; p < 0.001) and was still increased sevenfold (95% CI 2.9 to 16.7; p < 0.001) relative to placebo 9.5 hours after administration of the morning dose. No significant differences were noted for the PC35sGaw to histamine for pranlukast compared with placebo. CONCLUSIONS: This study shows that pranlukast is a potent and selective LTD4 receptor antagonist in humans which blocks LTD4 challenge after initial and repeated administration when given twice daily for five days.Keywords
This publication has 21 references indexed in Scilit:
- The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjectsJournal of Allergy and Clinical Immunology, 1993
- Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthmaRespiratory Medicine, 1993
- In Vitro Antagonism of ONO-1078, a Newly Developed Anti-Asthma Agent, against Peptide Leukotrienes in Isolated Guinea Pig Tissues.The Japanese Journal of Pharmacology, 1992
- Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjectsThe Lancet, 1991
- Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: Relationship to the development of late asthmatic responsesJournal of Allergy and Clinical Immunology, 1991
- Airway Responsiveness to Histamine and Leukotriene E4 in Subjects with Aspirin-induced AsthmaAmerican Review of Respiratory Disease, 1989
- URINARY LEUKOTRIENE E4 AFTER ANTIGEN CHALLENGE AND IN ACUTE ASTHMA AND ALLERGIC RHINITISThe Lancet, 1989
- The effect of an oral leukotriene antagonist L-649,923 on histamine and leukotriene D4-induced bronchoconstriction in normal man*1Journal of Allergy and Clinical Immunology, 1987
- Lung tissue receptors for sulfidopeptide leukotrienesJournal of Allergy and Clinical Immunology, 1984
- Structure of slow-reacting substance of anaphylaxis from guinea-pig lungNature, 1980